According to the American Society of Clinical Oncology guidelines, the 21-gene recurrence score Oncotype DX (ODX; Exact Sciences, Madison, USA) can be used to inform adjuvant chemotherapy decisions in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer [2]. This evidence concerns the gene ERBB2 and breast carcinoma.